Half-life extension technologies for haemostatic agents

The use of plasma-derived and recombinant coagulation factors for the treatment of haemophilia A and B is well established and permits patients to live a relatively normal life. In order to improve treatment options, several products are in development, which have a prolonged duration of action, thu...

Full description

Saved in:
Bibliographic Details
Published inThrombosis and haemostasis Vol. 113; no. 1; p. 165
Main Author Mannucci, Pier Mannuccio
Format Journal Article
LanguageEnglish
Published Germany 01.01.2015
Subjects
Online AccessGet more information

Cover

Loading…
More Information
Summary:The use of plasma-derived and recombinant coagulation factors for the treatment of haemophilia A and B is well established and permits patients to live a relatively normal life. In order to improve treatment options, several products are in development, which have a prolonged duration of action, thus enabling less frequent prophylactic dosing and aiming to reduce the burden of treatment. Several innovative approaches are being pursued to extend the half-life of factor VIIa, factor VIII and factor IX, utilising technologies such as Fc fusion, recombinant albumin fusion and addition of polyethyleneglycol (PEG) (PEGylation). These methods prolong the time in the circulation by reducing degradation and elimination. This review summarises the technologies and products in development and their stages of development, and also discusses their pros and cons.
ISSN:0340-6245
DOI:10.1160/TH14-04-0332